201 related articles for article (PubMed ID: 33820779)
1. Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer.
Lim B; Potter DA; Salkeni MA; Silverman P; Haddad TC; Forget F; Awada A; Canon JL; Danso M; Lortholary A; Bourgeois H; Tan-Chiu E; Vincent S; Bahamon B; Galinsky KJ; Patel C; Neuwirth R; Leonard EJ; Diamond JR
Clin Cancer Res; 2021 Jun; 27(12):3329-3338. PubMed ID: 33820779
[TBL] [Abstract][Full Text] [Related]
2. Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor.
García-Sáenz JÁ; Martínez-Jáñez N; Cubedo R; Jerez Y; Lahuerta A; González-Santiago S; Ferrer N; Ramos M; Alonso-Romero JL; Antón A; Carrasco E; Chen J; Neuwirth R; Galinsky K; Vincent S; Leonard EJ; Slamon D
Clin Cancer Res; 2022 Mar; 28(6):1107-1116. PubMed ID: 34980598
[TBL] [Abstract][Full Text] [Related]
3. A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer.
Schmid P; Sablin MP; Bergh J; Im SA; Lu YS; Martínez N; Neven P; Lee KS; Morales S; Pérez-Fidalgo JA; Adamson D; Gonçalves A; Prat A; Jerusalem G; Schlieker L; Espadero RM; Bogenrieder T; Huang DC; Crown J; Cortés J
Breast Cancer Res; 2021 Jan; 23(1):8. PubMed ID: 33451345
[TBL] [Abstract][Full Text] [Related]
4. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
5. Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR
Bardia A; Modi S; Oliveira M; Cortes J; Campone M; Ma B; Dirix L; Weise A; Hewes B; Diaz-Padilla I; Han Y; Deshpande P; Samant TS; Lorenc KR; He W; Su F; Chavez-MacGregor M
Clin Cancer Res; 2020 Dec; 26(24):6417-6428. PubMed ID: 32998962
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.
Tesch H; Stoetzer O; Decker T; Kurbacher CM; Marmé F; Schneeweiss A; Mundhenke C; Distelrath A; Fasching PA; Lux MP; Lüftner D; Hadji P; Janni W; Muth M; Kreuzeder J; Quiering C; Taran FA
Int J Cancer; 2019 Feb; 144(4):877-885. PubMed ID: 29992557
[TBL] [Abstract][Full Text] [Related]
7. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
[TBL] [Abstract][Full Text] [Related]
8. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis.
Bachelot T; McCool R; Duffy S; Glanville J; Varley D; Fleetwood K; Zhang J; Jerusalem G
Breast Cancer Res Treat; 2014 Jan; 143(1):125-33. PubMed ID: 24272078
[TBL] [Abstract][Full Text] [Related]
10. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial.
Rugo HS; Seneviratne L; Beck JT; Glaspy JA; Peguero JA; Pluard TJ; Dhillon N; Hwang LC; Nangia C; Mayer IA; Meiller TF; Chambers MS; Sweetman RW; Sabo JR; Litton JK
Lancet Oncol; 2017 May; 18(5):654-662. PubMed ID: 28314691
[TBL] [Abstract][Full Text] [Related]
11. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Tolaney SM; Wardley AM; Zambelli S; Hilton JF; Troso-Sandoval TA; Ricci F; Im SA; Kim SB; Johnston SR; Chan A; Goel S; Catron K; Chapman SC; Price GL; Yang Z; Gainford MC; André F
Lancet Oncol; 2020 Jun; 21(6):763-775. PubMed ID: 32353342
[TBL] [Abstract][Full Text] [Related]
12. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
13. Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.
Kornblum N; Zhao F; Manola J; Klein P; Ramaswamy B; Brufsky A; Stella PJ; Burnette B; Telli M; Makower DF; Cheema P; Truica CI; Wolff AC; Soori GS; Haley B; Wassenaar TR; Goldstein LJ; Miller KD; Sparano JA
J Clin Oncol; 2018 Jun; 36(16):1556-1563. PubMed ID: 29664714
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.
Yam C; Esteva FJ; Patel MM; Raghavendra AS; Ueno NT; Moulder SL; Hess KR; Shroff GS; Hodge S; Koenig KH; Chavez Mac Gregor M; Griner RL; Yeung SJ; Hortobagyi GN; Valero V
Invest New Drugs; 2019 Apr; 37(2):345-351. PubMed ID: 30610588
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study).
Wang J; Cai L; Song Y; Sun T; Tong Z; Teng Y; Li H; Ouyang Q; Chen Q; Cui S; Yin Y; Liao N; Sun Q; Feng J; Wang X; Xu B
Eur J Cancer; 2023 May; 184():73-82. PubMed ID: 36905771
[TBL] [Abstract][Full Text] [Related]
16. Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study.
Xie Y; Li Y; Zhang Y; Zhang S; Li W; Guan X; Zhao Y; Gong C; Hu X; Zhang J; Cao E; Wang L; Ge R; Wang B
Clin Breast Cancer; 2019 Jun; 19(3):e452-e458. PubMed ID: 30846408
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR
Bardia A; Hurvitz SA; DeMichele A; Clark AS; Zelnak A; Yardley DA; Karuturi M; Sanft T; Blau S; Hart L; Ma C; Rugo HS; Purkayastha D; Moulder S
Clin Cancer Res; 2021 Aug; 27(15):4177-4185. PubMed ID: 33722897
[TBL] [Abstract][Full Text] [Related]
18. Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.
Moy B; Neven P; Lebrun F; Bellet M; Xu B; Sarosiek T; Chow L; Goss P; Zacharchuk C; Leip E; Turnbull K; Bardy-Bouxin N; Duvillié L; Láng I
Oncologist; 2014 Apr; 19(4):346-7. PubMed ID: 24674873
[TBL] [Abstract][Full Text] [Related]
19. Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.
Jerusalem G; de Boer RH; Hurvitz S; Yardley DA; Kovalenko E; Ejlertsen B; Blau S; Özgüroglu M; Landherr L; Ewertz M; Taran T; Fan J; Noel-Baron F; Louveau AL; Burris H
JAMA Oncol; 2018 Oct; 4(10):1367-1374. PubMed ID: 29862411
[TBL] [Abstract][Full Text] [Related]
20. Everolimus Plus Letrozole for Treatment of Patients With HR
Safra T; Kaufman B; Kadouri L; Efrat Ben-Baruch N; Ryvo L; Nisenbaum B; Evron E; Yerushalmi R
Clin Breast Cancer; 2018 Apr; 18(2):e197-e203. PubMed ID: 29097108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]